People: Aquestive Therapeutics Inc (AQST.OQ)
23 Jul 2019
Mr. John T. Maxwell is Senior Vice President – Chief Financial Officer of the Company since January 2017. Prior to joining our team, Mr. Maxwell held senior financial roles at WIL Research, InfoNXX, PanAmSat, ADP and General Signal, including as Chief Financial Officer of WIL Research from September 2008 to April 2016. In addition, Mr. Maxwell served as a freelance consultant from April 2016 until January 2017. Mr. Maxwell started his career at Ernst & Young, serving in the Dallas, New York and Stamford offices. Mr. Maxwell helped lead the successful strategic sale transactions by the private equity sponsors of WIL Research in April 2016 to Charles River Labs and of PanAmSat in 2006 to Intelsat. Mr. Maxwell also helped lead the initial public offering of PanAmSat in 2005 and multiple public and private debt transactions for WIL Research, InfoNXX and PanAmSat. Mr. Maxwell is a licensed certified public accountant and holds a BBA in Accounting from Texas Tech University and an MBA in Finance and International Business from New York University Stern School of Business.
|Total Annual Compensation, USD||726,250|
|Restricted Stock Award, USD||874,335|
|Long-Term Incentive Plans, USD||--|
|All Other, USD||19,615|
|Fiscal Year Total, USD||1,620,200|